Nigral and adrenal grafts in parkinsonism: recent basic and clinical studies.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000313:Adrenal Medulla / Q000503:physiopathology*; D000818:Animals; D002421:Caudate Nucleus / Q000503:physiopathology; D002838:Chromaffin System / Q000503:physiopathology* / Q000637:transplantation; D004195:Disease Models, Animal; D004298:Dopamine / Q000502:physiology*; D006801:Humans; D009416:Nerve Regeneration; D009474:Neurons / Q000502:physiology; D010300:Parkinson Disease / Q000601:surgery; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000503:physiopathology*; D010622:Phencyclidine / Q000494:pharmacology; D011725:Pyridines / Q000633:toxicity; D011954:Receptors, Dopamine / Q000502:physiology; D013378:Substantia Nigra / Q000503:physiopathology*; D009435:Synaptic Transmission / Q000187:drug effects
D011725:Pyridines; D011954:Receptors, Dopamine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D010622:Phencyclidine; D004298:Dopamine